Kairos Pharma (KAPA) Cash From Financing

Annual CFF

-$425.00 K
-$1.14 M-159.27%

December 1, 2023


Summary


Performance

KAPA Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherKAPAcash flowmetrics:

Quarterly CFF

$5.22 M
+$5.07 M+3400.67%

September 30, 2024


Summary


Performance

KAPA Quarterly CFF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherKAPAcash flowmetrics:

TTM CFF

$5.20 M
+$5.44 M+2305.08%

September 30, 2024


Summary


Performance

KAPA TTM CFF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherKAPAcash flowmetrics:

Cash From Financing Formula

CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities

KAPA Cash From Financing Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-159.3%+7344.4%+1324.5%
3 y3 years-1248.7%+2073.3%+2068.3%
5 y5 years-1248.7%+2073.3%+2068.3%

KAPA Cash From Financing Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-159.3%at lowat high+2428.6%at high+1277.4%
5 y5-year-159.3%at lowat high+2428.6%at high+1277.4%
alltimeall time-159.3%at lowat high+2428.6%at high+1277.4%

Kairos Pharma Cash From Financing History

DateAnnualQuarterlyTTM
Sep 2024
-
$5.22 M(+3400.7%)
$5.20 M(-2305.1%)
Jun 2024
-
$149.00 K(-267.4%)
-$236.00 K(-46.6%)
Mar 2024
-
-$89.00 K(+23.6%)
-$442.00 K(+4.0%)
Dec 2023
-$425.00 K
-$72.00 K(-67.9%)
-$425.00 K(+14.9%)
Sep 2023
-
-$224.00 K(+293.0%)
-$370.00 K(-922.2%)
Jun 2023
-
-$57.00 K(-20.8%)
$45.00 K(-88.9%)
DateAnnualQuarterlyTTM
Mar 2023
-
-$72.00 K(+323.5%)
$405.00 K(-43.5%)
Dec 2022
$717.00 K(+23.6%)
-$17.00 K(-108.9%)
$717.00 K(-2.3%)
Sep 2022
-
$191.00 K(-37.0%)
$734.00 K(+35.2%)
Jun 2022
-
$303.00 K(+26.3%)
$543.00 K(+126.3%)
Mar 2022
-
$240.00 K
$240.00 K
Dec 2021
$580.00 K(+1467.6%)
-
-
Dec 2020
$37.00 K
-
-

FAQ

  • What is Kairos Pharma annual cash flow from financing activities?
  • What is the all time high annual CFF for Kairos Pharma?
  • What is Kairos Pharma annual CFF year-on-year change?
  • What is Kairos Pharma quarterly cash flow from financing activities?
  • What is the all time high quarterly CFF for Kairos Pharma?
  • What is Kairos Pharma quarterly CFF year-on-year change?
  • What is Kairos Pharma TTM cash flow from financing activities?
  • What is the all time high TTM CFF for Kairos Pharma?
  • What is Kairos Pharma TTM CFF year-on-year change?

What is Kairos Pharma annual cash flow from financing activities?

The current annual CFF of KAPA is -$425.00 K

What is the all time high annual CFF for Kairos Pharma?

Kairos Pharma all-time high annual cash flow from financing activities is $717.00 K

What is Kairos Pharma annual CFF year-on-year change?

Over the past year, KAPA annual cash flow from financing activities has changed by -$1.14 M (-159.27%)

What is Kairos Pharma quarterly cash flow from financing activities?

The current quarterly CFF of KAPA is $5.22 M

What is the all time high quarterly CFF for Kairos Pharma?

Kairos Pharma all-time high quarterly cash flow from financing activities is $5.22 M

What is Kairos Pharma quarterly CFF year-on-year change?

Over the past year, KAPA quarterly cash flow from financing activities has changed by +$5.29 M (+7344.44%)

What is Kairos Pharma TTM cash flow from financing activities?

The current TTM CFF of KAPA is $5.20 M

What is the all time high TTM CFF for Kairos Pharma?

Kairos Pharma all-time high TTM cash flow from financing activities is $5.20 M

What is Kairos Pharma TTM CFF year-on-year change?

Over the past year, KAPA TTM cash flow from financing activities has changed by +$5.63 M (+1324.47%)